Actinium Pharmaceuticals to Participate at the 37th Annual Roth Conference
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced it will participate at the 37th Annual Roth ...
Actinium Pharmaceuticals, Inc. (NYSE:ATNM) Receives $7.40 Consensus Price Target from Brokerages
Actinium Pharmaceuticals, Inc. (NYSE:ATNM – Get Free Report) has received a consensus rating of “Moderate Buy” from the five ...
BBN Times13d
Global Access to Actinium-225 PSMA Therapy: Where You Can Receive Treatment and What It Costs
Actinium-225 PSMA therapy is an emerging treatment for advanced prostate cancer that focuses on delivering targeted radiation ...
Actinium Pharmaceuticals initiates Actimab-A Triplet combination frontline trial
Actinium Pharmaceuticals (ATNM) announced that the first clinical trial under its previously announced Cooperative Research and Development ...
Actinium Pharmaceuticals (NYSE:ATNM) Earns “Buy” Rating from HC Wainwright
Actinium Pharmaceuticals (NYSE:ATNM – Get Free Report)‘s stock had its “buy” rating reaffirmed by investment analysts at HC Wainwright in a research note issued to investors on Tuesday,Benzinga ...
Nasdaq5d
Actinium Pharmaceuticals to Participate at the 37th Annual Roth Conference
NEW YORK, March 12, 2025 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced ...
Why Actinium-225 Radioligand Therapy is the Next Step for Non-Responders to Lutetium-177 in Prostate Cancer
Prostate cancer poses significant challenges for many patients. Radioligand therapies have offered hope by targeting cancer cells with precision. While Lutetium-177 therapy has been effective for many ...
H.C. Wainwright Sticks to Their Buy Rating for Actinium Pharmaceuticals (ATNM)
In a report released yesterday, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Actinium Pharmaceuticals (ATNM – Research ...
Investing6d
Actinium launches new AML treatment trial with NCI
NEW YORK - Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM), whose stock has declined over 83% in the past year according to InvestingPro data, has launched a clinical trial in collaboration ...
Kalkine Media4d
What Factors Are Driving Market Activity for Actinium Pharmaceuticals (NYSE:ATNM)?
Highlights,Actinium Pharmaceuticals operates in the biotechnology sector, focusing on targeted radiotherapies for oncology treatments.,Institutional participants have adjusted their holdings, ...